Get the Stockscreener App
13.99
4.31%
-0.63
After Hours:
13.89
-0.10
-0.71%
Evolus Inc stock is traded at $13.99, with a volume of 582.26K.
It is down -4.31% in the last 24 hours and up +3.78% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$14.62
Open:
$14.78
24h Volume:
582.26K
Relative Volume:
0.81
Market Cap:
$885.87M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-12.95
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-5.09%
1M Performance:
+3.78%
6M Performance:
-10.66%
1Y Performance:
+7.04%
1-Day Range:
$13.79
$14.78
1-Week Range:
$13.79
$15.06
52-Week Range:
$9.25
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
13.99 | 885.87M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Rice Hall James & Associates LLC Acquires 43,381 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit - BioSpace
Inside Evolus's Growth Strategy: CEO Takes Center Stage at Elite Beauty Summit - StockTitan
Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 - BioSpace
Evolus Sets Date for Key 2024 Financial Results: What the Beauty Industry is Watching - StockTitan
Evolus (NASDAQ:EOLS) Receives Buy Rating from HC Wainwright - MarketBeat
Legato Capital Management LLC Sells 43,769 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat
Evolus (NASDAQ:EOLS) Trading 15.3% HigherTime to Buy? - MarketBeat
Evolus's SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Australia
Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles - substack.com
Evolus's SWOT analysis: FDA nod for filler boosts stock outlook - MSN
Evolus’s SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Nigeria
(EOLS) Technical Data - Stock Traders Daily
Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? - MSN
FDA approves two hyaluronic acid fillers for nasolabial folds - Healio
FDA Approves Two New Hyaluronic Acid Dermal Fillers - Medical Dialogues
Breaking Down Evolus: 4 Analysts Share Their Views - Benzinga
A great week that adds to Evolus, Inc.'s (NASDAQ:EOLS) one-year returns, institutional investors who own 70% must be happy - Simply Wall St
Sector Update: Health Care -February 13, 2025 at 03:38 pm EST - Marketscreener.com
Evolus, Inc. Announces FDA Approval of Evolysse?? Form and Evolysse?? Smooth Injectable Hyaluronic Acid Gels - Marketscreener.com
Evolus Gets US FDA Approval for Injectable Hyaluronic Acid Gels -February 13, 2025 at 02:11 pm EST - Marketscreener.com
US FDA approves Evolus' anti-wrinkle gels - TradingView
US FDA approves Evolus' anti-wrinkle gels -February 13, 2025 at 02:02 pm EST - Marketscreener.com
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels - Business Wire
Game-Changing FDA Approval: Evolus Unveils Next-Gen Dermal Fillers That Outperform Restylane - StockTitan
With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing - Yahoo Finance
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace
Evolus (NASDAQ:EOLS) Trading Down 6.5%Here's Why - MarketBeat
Unlocking Beauty: Evolus Sparks Excitement with New Stock Awards for Employees! - Mi Valle
Acelyrin (NASDAQ:SLRN) versus Evolus (NASDAQ:EOLS) Financial Contrast - Defense World
Unlocking Beauty: Evolus Rewards New Talent with Stock Options and RSUs - Trabajo News
Evolus Unleashes Major Talent Expansion: 34 New Hires Secure Equity Stakes in Growth Push - StockTitan
BlackRock, Inc. Expands Stake in Evolus Inc with Strategic Acqui - GuruFocus.com
How the (EOLS) price action is used to our Advantage - Stock Traders Daily
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Barclays Issues Positive Forecast for Evolus (NASDAQ:EOLS) Stock Price - Defense World
Global Jeuveau Market Insights 2025: Key Trends, Market Size, and Growth Forecast - EIN News
Barclays Raises Evolus (NASDAQ:EOLS) Price Target to $22.00 - MarketBeat
Stifel maintains Buy on Evolus, price target steady at $25 - MSN
HC Wainwright Issues Optimistic Outlook for Evolus Earnings - Defense World
Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal
FY2029 Earnings Estimate for Evolus Issued By HC Wainwright - MarketBeat
HC Wainwright Weighs in on Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? - MSN
Evolus, Inc. (NASDAQ:EOLS) Soars 30% But It's A Story Of Risk Vs Reward - Simply Wall St
HC Wainwright Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS) - MarketBeat
4 Analysts Have This To Say About Evolus - Benzinga
Evolus projects robust 2025 growth with upcoming product launches By Investing.com - Investing.com Australia
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.23%
3.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):